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Two general kinds of liver transplantation have been 
attempted clinically. With one approach, the host liver is 
removed and replaced with a homograft (orthotopic liver 
transplantation); alternatively, an extra liver is inserted 
at an ectopic site (auxiliary homotransplantation). This 
review concerns only orthotopic liver transplantation. r The first effort to replace a human liver was made at 
! the University of Colorado on March 1, 1963. That pa-
tient died as did four others during the next 7 months (1, 
2) (Table 1). In September, 1963 and January, 1964, other 
unsuccessful attempts at liver replacement were made in 
transplantation occurred on May 2, 1968 when CaIne and 
Williams of the University Hospital at Cambriage and 
the King's College in London, reiDp~ctivdyI treated the 
first patient in their program (6, 7) which had since 
generated more than 125 well-studied cases. CaIne's con-
tributions in experimental renal transplantation has been 
a major factor in the early development (8) of chemical 
immunosuppression, without which transplantation of 
any organ was not realistic until 2 decades ago. The fact 
that both men had the personal qualities to be able to 
accept defeat or victory with equal grace was fortunate 
since failure was the dominant theme with all such efforts 
until recent times. \ 1",--
Boston (3) and Paris (4) (Table 1). The first clinical trials 
were not frivolously undertaken. Members of the Boston 
and Denver teams had developed techniques for liver 
replacement in dogs in the late 1950s and, in both labo-
ratories, research on liver transplantation had been con-
tinuously performed for more than 4 years. 
Nevertheless, the consecutive failures in three institu-
tions halted all clinical trials until our sixth and seventh 
equally unsuccessful attempts in October, 1966 and May, 
1967. Finally, on July 23, 1967, the first extended survival 
of a human recipient was achieved (5). The patient, a 1112-
year-old girl, lived for more than 13 months before dying 
of metastases from the hepatocellular carcinoma for 
which she had been treated. From then until the first 
week of May, 1982, we have treated 230 more patients, 
163 at the University of Colorado and 67 at the University 
Health Center of Pittsburgh for a total of 237. The yearly 
frequency of transplantation throughout our experience 
is shown in Figure 1. The highest number of 30 was 
reached in 1981; the number of new cases in 1982 is 
projected at between 60 and 80. 
A signal event in the development of orthotopic liver 
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In this review, emphasis will be placed on the more 
than 350 cases in these two series. However, between 
1968 and 1978, other single attempts or small series were 
reported from Boston (9, 10), Los Angeles (11), Montreal 
(12), Bonn (13, 14), Sao Paulo (15), Calgary (16), New 
York City (17), Richmond (18), Minneapolis (19), Man-
chester (20), and Oslo (21). It is probable that these 
documented cases were a minority of those attempted in 
that decade, exclusive of the English and Colorado series. 
Since 1978, programs have been reopened or started new 
from which important information can be expected. -In 
the United States, clinical liver transplantation programs 
are active at the University of Minnesota (J. S. Najarian, 
,unpublished observations) and the University of Tennes-
\see (J. W. Williams, unpublished observations). Series of 
'six or more cases each have been reported or are in 
preparation from Holland (22), East Germany (23), West 
Germany (24,25), France (26), and the Republic of China 
(H. Q. Hong, unpublished observations). The number of 
cases in the West German series (25) has passed 50, but 
the results have not yet been published in detail. 
EARLY EXPERIMENTAL BACKGROUND 
The first known efforts at experimental orthotopic 
transplantation of the liver were made by Dr. Jack Can-
non of Los Angeles (27). This report was so brief that it 
lacked a title, description of methods, and notation of the 
animal species. The animals did not survive operation. 
614 
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TABLE l. THE FIRST TRIALS OF ORTHOTOPIC LIVER TRANSPLANTATIONS 
No. Location 
Age 
(ref.) (yr) Disease 
Survival 
(days) 
------------- -------------
Main cause of death 
---------------------- ------
2 
3 
4 
.') 
6 
7 
72 
64 
56 
48 
a: 
4: 
w 
>- 40 
>-(J) 
en 32 w 
en 
4: 
() 
24 
16 
8 
Denver (1) 3 Extrahepatic biliary atresia 
Denver (1) 48 Hepatocellular cancer, cirrhosis 
Denver (1) 68 Duct cell carcinoma 
Denver (2) 52 Hepatocellular cancer. cirrhosis 
Boston (;3) 58 Metastatic colon carcinoma 
Denver (2) 29 Hepatocellular cancer, cirrhosis 
Paris (4) 75 Metastatic colon carcinoma 
~ RetransplantatlOn 
6 Primary Orthotopic Transplantation 
63 6465 66 67 68 6970 71 72 73 74 75 76 77 78 79 80 81 82 
YEARS 
FIG. 1. Yearly number of liver transplantations at the University of 
Colorado (1963 to 1980) and the University of Pittsuurgh (1981 to 
1982). Note that retransplantation has been attempted frequently. 
In June, 1958, a program of orthotopic transplantation of 
the canine liver was initiated at the Peter Bent Brigham 
Hospital under the direction of Dr. Frances D. Moore 
(28), and in August, our first experiments in the same 
species were begun at Northwestern University in Chi-
cago (29,30). 
The technical problems of liver replacement and the 
features of rejection in untreated canine recipients were 
delineated (28-31). Eventually, using immunosuppres-
sion with azathioprine (32-34) and antilymphocyte serum 
or its antilymphocyte globulin (ALG) derivative (32, 
35-38), chronic survival was achieved in mongrel dogs of 
which one lived for almost 12 years (39). 
In 1965, Garnier of Paris (40) made the important 
observation that rejection of pig liver homografts was 
mild in comparison to that in dogs. Several porcine 
recipients lived for long times without immunosuppres-
sion. Workers in Bristol (41), Cambridge (42), and Denver 
(32) promptly confirmed Garnier's work. The value of 
the pig for transplantation research has been demon-
strated frequently in the investigations of CaIne and his 
associates. 
Hundreds of significant experimental studies in various 
species have since been published. Review of this work 
o Hemorrhage 
22 Pulmonary emboli, sepsis 
7'/, Sepsis, pulmonary emuoli, gastrointestinal 
bleeding 
SD~ Pulmonary emboli, ? hppatic failure, pul-
monary edema 
11 Pneumonitis, liver abscesses, hepatic failure 
23 Sepsis, bile peritonitis, hepatic failure 
o Hemorrhage 
will not be attempted although some of it has influenced 
the clinical trials as will be noted later. 
NOTATIONS ABOUT SURGICAL TECHNIQUES 
IN HUMANS 
A training period in the animal laboratories is an 
important preparatory step for teams planning clinical 
programs; however, not all of the experimental tech-
niques are identical in humans. Our methods of ortho-
topic liver transplantation (1, 5, 32, 43-52) and the mod-
ifications introduced by CaIne et a1. (6,47, 53) have been 
described. 
The operation is simple in principle (Figure 2), but its 
execution has been exceptionally difficult because of the 
almost invariable debilitation of the recipients and the 
profoundly abnormal vascularization patterns caused by 
portal hypertension in endstage liver disease. Defects in 
clotting have been present in most. cases (1,32,54; 55), 
and adhesions or other alterations secondary to previous 
operations are often complicating factors. With such a 
background, it is not surprising that the postoperative 
care of many patients has been an exercise in resuscita-
tion (32). The most common difficulties have been pul-
monary insufficiency (requiring mechanical ventilation 
for several months in some cases), renal failure with 
massive fluid shifts, and persistent clotting abnormalities. 
These problems are managed with conventional methods 
of intensive care with emphasis on biochemical and he-
modynamic monitoring. Recovery can be expected from 
encephalopathy and the hepatorenal syndrome (50). 
The ability to survive this critical period depends upon 
what has transpired in the operating room. Thus, in the 
following remarks, we will touch upon details of surgical 
technique which require reemphasis or points of view 
which have changed from those expressed in the past. 
ORGAN PROCUREMENT AND PRESERVATION 
Until 1976, techniques for preserving the liver either 
severely limited the acceptable time of cold ischemia or 
were too complicated for use in outlying hospitals (32). 
In 1976, simple methods that permitted reasonably long 
storage were developed, and clinical trials were started. 
W e have employed an electrolyte (Collins) solution with 
a composition similar to that found intracellularly (57). 
The Cambridge-King's College team uses a plasma so-
lution for similar cold infusion of the homograft (58). In 
dogs, the two methods yielded similar results (57) and 
allowed safe preservation for up to 12 hr. These tech-
--------------- ---_._---------
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FIG. 2. Completed orthotopic liver transplantation. (A) Biliary tract reconstruction with choledochocholedochostomy. (B) Biliary tract 
reconstruction with choledochojejunostomy, using a Houx limb. 
niques permit shipment of livers from city to city. More 
than two-thirds of the livers used in the Pittsburgh 
program have been obtained outside of the normal pro-
curement area for this region; the longest transit being 
from Phoenix, Ariz. Efficient air travel arrangements are 
necessary; to meet this objective, several Pittsburgh cor-
porations have donated their private jet airplanes. 
Liver procurement outside of the local area has de-
pended on cooperation with other procurement centers 
whose main function was previously to provide cadaveric 
kidneys. Fear that ki.dney grafts would be jeopardized by 
giving too high a priority to the liver has been allayed by 
standardization of techniques which protect all organs 
equally and which can be adapted to the local surgeons' 
wishes (59). 
A midline inci.sion is made from the pubis to the neck, 
and the sternum is split. The structures entering and 
leaving the liver are skeletonized, and the necessary 
preliminary steps for kidney removal are taken in the 
presence of an intact circulation. Then a cannula is 
placed through the splenic vein into the superior mes-
enteric vein. Rapid infusion of cold lactated Ringers' 
solution is used to start cooling of the liver. After 1 or 2 
liters have been infused, cold Collins solution is infused 
through the terminal aorta at the same time as the distal 
thoracic aorta is cross-clamped and the cadaveric donor 
is exsanguinated from a cannula previously placed in the 
distal inferior vena cava. After removal, the cold liver is 
flushed with Collins solution and protected by a plastic 
bag which is placed in slushed ice. The performance of 
kidneys removed from liver donors with this technique 
was as good or better than has been achieved in most 
centers with kidney removal alone (59). With minor 
modifications, it has also been possible to remove the 
heart in addition to kidneys and liver from seven donors. 
During 1981 when 30 liver homografts were used, there 
were 176 offers of organs. The inability to use the other 
146 livers was usually because there was a disparity in 
size between the donor and recipient, the donor blood 
group was incompatible with the recipient, or Pittsburgh 
facilities for liver recipient care were saturated. An actual 
shortage of pediatric donors has existed in the 1- to 5-
year age group. 
RECIPIENT HEPATECTOMY 
The most demanding aspect of liver transplantation is 
removal of the diseased native organ. The technical 
difficulties are usually determined by the underlying 
disease. The easiest situations are in patients with pri-
mary hepatic malignancies or primary biliary cirrhosis. 
The most difficult are in recipients with the shrunken 
livers of macro nodular cirrhosis or in patients with mul-
tiple previous operations. On the average, hepatectomy 
is easier in infants and children than in adolescents and 
adults. 
The preexisting pathologic changes often necessitate 
--------------
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inization, bleeding has not been excessive since the 
"heparin effect" can be effectively reversed even in pa-
tients with severe liver disease. 
deviations from a standard plan; however, the first step 
is to find the hilum and de arterialize the liver which 
expedites hilar dissection and slows hemorrhage from the 
liver surface. During hilar dissection, the bile duct is BILIARY TRACT RECONSTRUCTION 
transected as high as possible so that the option of duct-
to-duct anastomosis is retained. The portal vein is left Difficulties with biliary tract reconstruction were fre-
intact until later, in order not to aggravate the portal quently lethal in our experience (43, 62, 63) and in that 
hypertension. of the English workers (7, 49-51) until the mid-1970s. 
The inferior vena cava below the liver is encircled with Anatomic studie~ by Terblanche et al. (64) suggest that 
minimal dissection. The left triangular and falciform deficient blood supply of the homograft duct system may 
ligaments are incised until the suprahepatic vena cava is be a contributory factor; however, our princi.pal problems 
identified. The suprahepatic vena cava is encircled to were due to the frequent (and inappropriate) use of 
allow placement of a cross-clamp. cholecystoduodenostomy and to failure to diagnose the 
If all of these maneuvers are successfully executed, the complications. The latter deficiency was resolved with 
liver can be isolated from the circulation by cross-clamp- the frequent use of postoperative cholangiography (Fig-
ing vessels which have been encircled but are intact. ure 3) and reoperation, if necessary. The incidence of 
Cuffs of the suprahepatic and infrahepatic vena cava are complications has been reduced with better primary re-
fashioned from these vessels as the liver is removed. construction. 
Sufficient infrahepatic vena cava is not difficult to obtain, We now consider duct-to-duct anastomosis to be the 
but development of an adequate suprahepatic cuff may procedure of choice (Figure2A). When this is not feasible, 
require tailoring of the vena cava which is mobilized from the duct is anastomosed to a Roux limb of jejunum 
within the liver (46). The technique of isolating the liver , (Figure 2B). With either technique, the homograft gall-
and peeling it out in a bloodless state permits all residual .r· bladder is removed. The results of biliary tract recon-
tissue connections of the right triangular ligament and . struction in the last 67 cases are shown in Table 2. Using 
the bare areas (including the right adrenal vein) to be ;; choledochocholedochostomy or choledochojejunostomy, 
ligated under direct vision. The penalty with this ap- ' an eventually satisfactory result was obtained in more 
proach is an increase (usually about 30 min) in the time than 95% of cases, although the use of an internal stent 
of portal and vena caval cross-clamping, compared to (instead of aT-tube stent) for duct-to-duct anastomoses 
cross-clamp time with previously described techniques led to a high rate of reo per at ion. Only two deaths resulted 
(1, 32,43). directly from biliary tract reconstruction. 
Such cross-clamping is usually tolerated in patients Since 1976, CaIne et al. (48) have used a technique in 
with chronic disease in spite of major declines in cardiac which the homograft common duct and gallbladder are 
output and variable hypotension (60): the same thing has fashioned into a common channel and anastomosed to 
been demonstrated in dogs subjected to chronic bile duct recipient common duct or a Roux limb. Waddell and 
obstruction (61). Because of this, venous bypasses which Grover (65) had described such a common channel pro-
were used in our first cases were discontinued (1, 2). cedure for difficult biliary tract problems. 
Some patients are jeopardized by the venous cross-
clamping. If severe hypotension occurs after cross-clamp- THE QUESTION OF SPLENECTOMY 
ing, CaIne et al. (52, 53) recommend femoral vein-to-
femoral artery bypass with an intervening oxyg~natorK 
About 10% of the English patients are so treated. One 
death in our last 67 patients (01' 233, Table 14), as well 
as a cardiac arrest which was successfully treated, may 
have been avoided by this precaution. 
The spleen was removed in most of our early patients, 
in part to achieve immunodepression, but mainly to 
relieve hypersplenism and leukopenia which prevented 
the effective use of azathioprine or cyclophosphamide 
(32). With the advent of cyclosporin A, splenectomy was 
discontinued. 
The fact that most patients recover from portal and 
. f' . UNTREATABLE COMPLICATIONS 
vena 1Il enor caval cross-clamping may have created a 
false impression about the safety ofthis practice. Usually, 
there is gross swelling of the intestine during the period 
of occlusion. Subsequently, many patients suffer from 
third-space fluid sequestration and postoperative renal 
failure. The extent to which these complex physiologic 
events contribute to the high perioperative mortality has 
not yet been delineated. For this reason, we returned in 
recent cases (not reported in this communication) to the 
practice of venous bypass which had been abandoned. 
Cannulas are placed into the inferior vena cava through 
an iliac or femoral vein and into the portal system 
through the open end of the transected portal vein. 
During the anhepatic phase, the blood is returned to a 
reservoir and pumped to a large vein in the neck or arm. 
Although this kind of bypass requires total body hepar-
Technical complications that have occurred after liver 
transplantation are legion. All have been potentially 
treatable except for irreversible ischemic injury of the 
graft or early loss of its blood supply. Retransplantation 
is the only hope for a patient who has been given an 
irreversibly damaged or devascularized organ. In one of 
our patients, portal vein stenosis at the anastomosis was 
diagnosed 8 months after transplantation, and, at reop-
eration, the stenosis was successfully resected in spite of 
the fact that thrombosis had occurred requiring throm-
bectomy (Figure 4). 
TISSUE MATCHING 
The time constraints of liver preservation and urgent 
recipient need usually preclude systematic efforts at tis-
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sue matching. With the random donor-recipient pairing, 
good mat.ches at the A, B, and DR loci have never been 
obtained . 
Hepatic transplantation has been performed (45, 50, 
51, 66) against the recipient anti-donor T-warm anti-
bodies which cause hyperacute rejection of kidney hom-
ografts. To our knowledge, hyperacute rejection of the 
liver has never been seen. 
However, much more experience will be required be-
fore concluding that acceptance of "positive cross-
matches" against T -warm recipient antibodies is without 
jeopardy. Data from the first 53 Pittsburgh cases is 
summarized in Table 3. Patients for whom cross-matches 
could not be performed or whose sera cross-matched 
negative with recipient cells had better results than those 
with cross-match positive donors. Although hyperacute 
rejection was not observed in the latter recipients, the 
FIG . 3. BlIiary obstruction 8 months 
after liver transplantation and a duct-to-
duct reconstruction in a IO-year-old 
chlld . Note the ectasia of the recipient 
common duct (arrow). At reoperation, 
the graft common duct was anas tomosed 
to a Roux limb of jejunum with a good 
result. 
postoperative courses were stormy. At least two of the 
livers developed delayed massive necrosis. 
From experimental studies, it is known that the liver 
is resistant to hyperacute rejection. However, in animal 
xenograft models in which the recipient has performed 
heterospecific cytotoxins, humoral antibody rejection of 
the liver is merely slower than that of the kidney; the 
mechanisms of destruction are the same. The extent (if 
any) to which the ou tlook after clinical liver transplan-
tation is depreciated by preformed antibodies is un-
known; many liver candidates have widely reacting T-
warm cytotoxic antibodies which reflect sensitization by 
previous blood transfusions. For the time being, we con-
tinue to treat such highly sensitized patients. 
If donor-recipient ABO blood group incompatibility 
exists, renal grafts can be destroyed by isoagglutinins 
(67). Liver grafts are resistant to this kind of hyperacute 
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TABLE 2. PRIMARY BILE DU CT PROCF:DURES AND COMPLICATIONS IN 75 LIVER TRANSPLANTATIONS ON 67 CONSECUTIVE PATIENTS 
IN THE CYCLOSPORIN ERA 
Choledochochole- Choledochochole- Choledoc hojejunos- Cholecystojej u nos-
tomy in Roux -en- Y 
External tube 
drainage 
Biliary reco n!=; tru(' -
tio n not completed 
(intrauperative 
d,·nth) 
doc hostomy with dochos tOOl.Y with tomy in R oux -en- Y 
T -tube internal s tent with s te nt 
No. 25 19 20 6 3" 2 
Success 20 11 18 
(80%) (58%) (90%) (17%) 
Failure 5 8 2 5 
Heoperat.ion require d 4" 7" 2 5 
Calise of death 0 0 
Nature of failure 
Obstruction J 0 4' 
Bile lea kage 4 4 2 1 
Arterioductal listula 0 1 0 0 
" Reconstruction was never completed in 2 of the J pa t.ients. 
/. One patipnt was treat ed with transhepatic dil a tion under X-ray control. 
, One pa t ient developed a large fUllga lliver abscess, which led to retransplant a t.ion. He is doing well with the second liver graft 1 year later. 
Flc. 4. (a ) Stenosis o f the port a l vein an as tomosis ( arrow) diagnosed by transhepatic portography in the same patient whose biliary sys tem is 
shown ill Fig. J. (b) Operative venogram obtained t.hrough a mesenteric vein a few days later. The obstruction was complete, a nd the homograft 
portal vein was full of thrombus. (c) Patent s.ys tem after resection of the sterosis, thrombectomy, and reanastomosis. 
qAei~: J. INFLUE:-:CE OF' TRAN SPLANTATION AGAINST DONOR-
SPI'TIF'IC CYTOTOXIC T-WARM ANTIBODIF:S (CY CLOSPORIN ERA) " 
Survival (mo nth!") 
No. 
> 2 Ii >12 l\'ow 
Negative cross - 31 24 22 14 3 21 
mat c h (77Cr ) (68C; ) 
Posit i vtl <.:1'0$$- 8 5 5 :2 4 
match Ed;g c~ ) (63 c;,, ) (50(;() 
C ross-m ll tch not 14 13 10 :2 12 
do ne (93<; ) (86Cr ) 
" Data fro m 5J co nsecutive primar.Y transplants at the Unive rs ity of 
Pittsburgh_ 
rejection (45). In two of our Pittsburgh cases, two incom-
patible donors were used (Table 4). The course of one of 
these patients is shown in Figure 6. We have tried to 
avoid this practice since blood group compatible donors 
can usually be found. 
TABL F: 4 . CASES l~D DONOR-RECIPIENT BLOOD GRO UP 
INCOMPATI HILITY IN 53 CONS ECUTIVE PRIMARY LIVER 
TRANSPI.ANTATIONS AT THE l NIVERSITY OF PITTSBURGH 
OT 
193 
1% 
lncornp;-uibil-
il ,v 8aft,\' grnft run et ion 
Good 
Good 
Outcome 
Well , 12 months 
Died, sys temic aspe rgil-
losis, 8 d a ys 
IMMUNOSUPPRESSION FOR HUMANS (THE 
KIDNEY TRANSPLANT PROTOTYPE) 
It was important to demonstrate in animals that 
chronic survival is possible after liver transplantation 
under immunosuppression. However, such laboratory in-
vestigations contributed relatively little to the immuno-
suppressive regimens which have been used clinically. 
Liver transplantation, either in animals or man, was too 
complex to be used as a model to evaluate drugs or drug 
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combinations. Instead, all methods to prevent or reverse 
rejection of whole organs have depended upon observa-
tions after renal transplantation. 
The immunosuppressive protocols that have been de-
veloped for human renal transplantation are summarized 
in Table 5, exclusive of the historically important trials 
with total body irradiation (68). Because the first genu-
inely promising drug, azathioprine (8), proved to be ef-
fective only rarely when given alone (69), the "modern" 
era was not entered until it was realized that azathioprine 
and prednisone have an additive (or possibly synergistic) 
effect (67, 70-73). At the outset, our policy was to begin 
therapy after renal transplantation with azathioprine and 
to add high doses of prednisone with the first signs of 
rejection (70). Because it was rare to escape rejection 
even after transplantation from closely related donors, 
our recommendation (67) was to begin treatment with 
both drugs immediately after transplantation with a 
gradual reduction in prednisone. Such "double-drug ther-
apy" has been the most commonly used immunosuppres-
sion for almost 20 years. 
With transplantation from consanguineous donors un-
der double-drug treatment, chronic renal graft function 
was achieved almost immediately in more than two-
thirds of cases. However, during the first year after 
cadaveric renal transplantation, the graft loss rate in 
multicenter compilations remains at about 50% (74, 75). 
Liver recipients for whom cadaveric donors were obliga-
tory, and who did not have the option of fall-back main-
tenance on an artificial organ therapy analogous to renal 
dialysis in the event of rejection, were confronted with a 
bleak outlook. 
Between 1963 and 1979, several alternative therapeutic 
programs were introduced for renal transplantation 
(Table 5); all were modifications of or additions to the 
original double-drug therapy. A promising approach in-
volved lymphoid depletion with ALG (36) which was 
given i.m. or i.v. as an adjunct to azathioprine and pred-
nisone during the first few weeks or months when the 
risk of rejection is the greatest. "Triple-drug therapy" 
has been the second most commonly used technique of 
immunosuppression. A conceptually important but prag-
matically inconsequential detail was that cyclophospha-
mide could be freely substituted for azathioprine (76). 
The results of I-year graft survival after cadaveric renal 
transplantation under triple-drug therapy were improved 
in most centers. After the discontinuance of ALG, there 
was an unacceptable rate of delayed rejection which, not 
surprisingly, also occurred after liver transplantation 
(32). The alternative of temporary lymphoid depletion 
with thoracic duct drainage (TDD) (77) in preparation 
of patients for cadaveric renal transplantation (78) had 
the same disadvantage (79). Efforts to use preoperative 
TDD in liver recipients usually created insurmountable 
problems because of the prodigious quantities (as much 
as 2 liters per hr) of thoracic duct lymph which patients 
with hepatic insufficiency produced (80). Lymphoid de-
pletion by total lymphoid irradiation for conditioning 
before grafting (81, 82) has not been tried in liver recipi-
ents. 
There was widespread discontent with all techniques 
of immunosuppression from 1963 to 1978. Many kidney 
transplant surgeons attempted to escape the conse-
quences of this therapeutic cul de sac by exploiting 
developments in tissue typing and matching, or by sys-
tematically conditioning prospective renal recipients 
with preoperative blood transfusions. The former efforts 
yielded disappointing results after cadaveric kidney 
transplantation; the latter practice of conditioning by 
transfusion allowed an increased success rate in patients 
not accidentally sensitized during their preparation. In 
any event, liver transplantation candidates usually were 
too ill to wait for a well-matched liver or to undergo 
stages of preoperative preparation. For future trials of 
liver transplantation, it was necessary to hope for better 
immunosuppressive drugs. This did not seem realistic 
until the advent of cyclosporin A. 
Cyclosporin A is an extract from the fungi Cylindro-
carpon lucidum and Trichoderma polysporum. It was 
discovered and characterized biochemically by scientists 
at the Sandoz Corp., Basel, Switzerland. Cyclosporin A 
was shown to be immunosuppressive by Borel et al. (83, 
84) in mice, rats, and guinea pigs. The drug depressed 
humoral and cellular immunity with a preferential and 
quickly reversible action against T-Iymphocytes. These 
effects were not accompanied by bone marrow depression 
which frequently limits the doses of azathioprine and 
cyclophosphamide. The unusual effectiveness of cyclo-
sporin A in preventing or delaying rejection of mouse 
skin homografts was demonstrated by Borel et al. (83, 
TABLE 5. CLINICAL IMMUNOSUPPRESSIVE DRUG l{EGIMEt-."S DEVELOPED WITH KIDNEY TRANSPLANTATION 
Agents 
Azathioprine 
Azathioprine-Steroids 
Thoracic duct drainage as 
adjunct 
ALG as adjunct 
Cyclophosphamide substitute 
for azathioprine 
Total lymphoid irradiation 
Cyclosporin A alone 
Cydosporin A-Steroids 
Year descrihed and re-
ported 
1962 (69) 
196:; (70-7.1) 
1963 (77)" 
1966 (a6) 
1970 (76) 
1979 (81,82) 
1978-1979 (90, 91) 
1980 (92, 93) 
Place 
Boston 
Denver, Boston, Hichmond, 
Edinborough 
Stockholm 
Denver 
Denver 
Palo Alto, Minneapolis 
Cambridge 
Denver 
Deficiencies Usen for liver transplantation 
Ineffective, dangerous 
Suboptimal 
Nuisance; requires 20-30 days pre-
treatment 
Still suboptimal 
No advantage except for patients 
with azathioprine toxicity 
Dangerous; extensive preparation; 
not quickly reversible 
Suboptimal 
Under evaluation 
No 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
" It was not realized until much later that pretreatment for 3 to 4 weeks before transplantation was a necessary condition (78). 
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84). Analogous observations in which heart, kidney, liver, 
and pancreatic grafts were protected in rats, rabbits, 
dogs, and pigs were reported by Kostakis (85), Calne 
(86-88), and Green (89) and their associates. 
When cyclosporin A was first used in patients by CaIne 
and coworkers (90,91), it was hoped that no other drug 
would be routinely required. Our dissenting opinion is 
that cyclosporin A should be combined with steroid 
therapy from the outset (92, 93). The extent to which 
steroids are required with cyclosporin A remains to be 
clarified, but it is clear that kidney survival of greater 
than 80% can be expected 1 year after primary cadaveric 
transplantation (93,94). Long-term follow-up of our orig-
inal recipients and those of CaIne has not shown a 
tendency for patients under cyclosporin A to have "catch-
up" graft losses or unexpected delayed morbidity from 
other causes. We and CaIne have not had the disillusion-
ment reported by Carpenter et al. (95) and Sweny et al. 
(96) in their first trials with cyclosporin A for cadaveric 
renal transplantation. 
As new teams begin using cyclosporin A, it will be 
important to avoid unrealistic expectations about early 
convalescence that could be engendered by the high 
success rates achieved after cadaveric renal transplanta-
tions. In a recent analysis of 42 consecutive cadaveric 
renal recipients (97), only one-third had a completely 
uneventful recovery. Of the remainder, most developed 
rejection which was usually reversed with augmented 
steroid therapy. In every case, the major differential 
diagnosis was rejection vs. nephrotoxicity from cyclo-
sporin A. 
Nephrotoxicity of cyclosporin A was first noted by 
CaIne (90, 91) and Powles (98), and has been confirmed 
elsewhere (92, 99). To sharpen the interrelationship be-
tween therapeutic effect and toxicity, pharmacologic (cy-
closporin A blood and/or plasma levels) and immunologic 
monitoring were advocated by Keown (100), Rynasiewicz 
(101), and Kahan (102). Our techniques of management 
have not depended upon these monitoring techniques. 
Fortunately, nephrotoxicity usually has promptly re-
versed with reduction of cyclosporin A doses. As a last 
resort, a change from cyclosporin A to azathioprine has 
been made but at an increased risk of rejection (99). 
Most other side effects of cyclosporin A (90-94) are not 
serious and include gingival hyperplasia, tremor, regional 
flushing or vague abdominal discomfort just after drug 
ingestion, and development of breast fibroadenomas in 
women. Although hepatotoxicity occurs in about one-
fifth of cases (l03), it is rarely serious enough to neces-
sitate a change to azathioprine. 
The most publicized question about cyclosporin A 
concerns its potential oncogenicity. It has been known 
for 15 years that conventional immunosuppression re-
sults in an increased incidence of de novo tumors, of 
which approximately one-third are lymphomas (104). 
Early reports by CaIne (91) of lymphoma development 
in patients treated with cyclosporin A were not surpris-
ing, although the incidence of three lymphomas in 34 
recipients was sobering. CaIne attributed this high inci-
dence to the concomitant use of other cytotoxic drugs 
and possibly steroids. In our own experience with cyclos-
porin A and steroid therapy in almost 200 cadaveric renal 
recipients, there have been two lymphomas. One was an 
incidental finding at autopsy following a fatal infection 
(93). The other was successfully treated by intestinal 
resection after it had caused a perforation (97). To our 
knowledge, no de novo epithelial tumors have been seen 
in renal recipients. As experience with cyclosporin A 
accumulated worldwide, the spectre of this drug being a 
spectacular tumor producer has receded. None of the 
liver recipients treated with cyclosporin A and steroids 
has developed new malignancies. 
IMMUNOSUPPRESSION AND LIVER 
TRANSPLANTATION 
Two patients are known to have been given orthotopic 
liver grafts without imrilUnosuppression or with steroid 
therapy only. The first patient was in the Cambridge 
series (7); the other was treated in Oslo (21). One factor 
in these decisions may have been the demonstration in 
dogs (32, 33) and pigs (32, 40-42) that rejection of liver 
grafts was less severe than that after renal transplanta-
tion. In addition, the English recipient had hepatitis 
which it was feared would be reactivated by immuno-
suppression. Both organs promptly failed with early 
death of the patients. 
All other patients were given some variant of the 
double- or triple-drug treatment summarized in Table 5. 
Our first five recipients and occasional ones later were 
treated with azathioprine and prednisone. The same 
treatment was used for almost all patients in the Cam-
bridge series from 1968 through 1979. 
Triple-drug treatment was used in the majority of 
recipients from 1966 through' 1979. The most common 
regimen was azathioprine, prednisone, and a variable 
course of i.m. ALG which was begun on the day of 
operation. The duration of ALG was usually limited to a 
few weeks because of sensitization of the recipients to 
horse, rabbit, or goat globulin; however, treatment with 
ALG was continued in some cases for 6 to 12 months. 
In a modification of triple-drug therapy (Table 5), 
cyclophosphamide instead of azathioprine was given to 
16 patients (OT 42-57) from March, 1971 to August, 1972 
(105). Six (37.5%) recipients lived for at least 1 year, aI).d 
four (OT 42,46, 53, 56) are still alive more than 10 years 
later. From a few months to several years after trans-
plantation, all surviving patients were switched to aza-
thioprine. Because the results during this period were 
not markedly different than with the original triple-drug 
management, cyclophosphamide was not further used as 
a first line drug. 
In 1978 and 1979, TDD was used as an adjunct to 
therapy with azathioprine and prednisone in 21 patients 
(80). TDD was started 10 to 18 days before transplanta-
tion in 2 patients, on the day of operation in 17 patients, 
and 2 and 4 weeks after transplantation in the other two. 
Six (31.6%) of 19 recipients who had TDD started prior 
to or on the day of transplantation lived for at least 1 
year and five are alive after 32/:3 to 41/:1 years. The man-
agement dilemma was that in the kidney transplantation 
model, TDD was ineffective unless applied at least 3 
weeks in advance of transplantation (78), but potential 
liver recipients could not tolerate the chronic, high-vol-
ume thoracic lymph drainage associated with hepatic 
622 ST ARZL ET AL. HEPATOLOGY 
disease. If TDD is to be tried again in liver transplanta-
tion, a closed system will be required in which lympho-
cytes can be removed in transit without the necessity for 
lymph removal and later reinfusion. 
CaIne et al. (91) were the first to use cyclosporin A for 
liver transplantation. In their first two cases, cyclosporin 
was used alone. However, most of their experience has 
been with delayed administration of the drug (53, 106). 
Azathioprine (1.5 mg per kg per day) and prednisolone 
(0.4 mg per kg per day) were used until renal and hepatic 
functions were adequate. Then, cyclosporin A (10 mg per 
kg per day) was begun, and the steroid dose was slowly 
reduced to zero. The supervention of acute rejection 
during treatment with azathioprine and prednisone was 
troublesome and, in the last review by CaIne et al. (53), 
they recommend shortening this period. 
Our practice (107-109) has been to start cyclosporin A 
a few hours preoperatively with an p.o. dose of 17.5 mg 
per kg (Figures 5 to '7). Cyclosporin A is continued daily, 
but with reduced i.m. or i.v. quantities (Figure 7) until 
p.o. diet is resumed. Subsequently an p.o. dose of 17.5 
mg per kg per day is given, usually with half the daily 
dose every 12 hr. The quantities are reduced subse-
quently if toxic manifestations develop, of which neph-
rotoxicity has been the most important (Figures 5 and 
6). Usually, steroids are also started on the day of oper-
ation. For adult patients who leave the operating room 
in relatively good condition, a 5-day burst of prednisolone 
is given, starting at 200 mg and stopping with a mainte-
nance dose of 20 mg per day (Figure 5). Further reduc-
tions of cyclosporin A and steroid doses are made on an 
individualized basis. Initial and maintenance therapy 
with steroids are reduced in infants and children (Fig-
ure 6). 
If the patient was in poor postoperative condition, the 
initial burst of high-dose steroid therapy was omitted for 
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a few days or greatly reduced (Figure 7). A few patients 
suspected of having nephrotoxicity from cyclosporin A 
were switched temporarily to azathioprine with resump-
tion of cyclosporin A treatment as renal function im-
proved (Figure 6). With less severe renal impairment 
(Figures 5 and 7), the dose of cyclosporin A was reduced. 
No patient has been changed to azathioprine perma-
nently. If rejection occurred in spite of this therapy, the 
principal responses have been to administer intermit-
tently large i.v. doses of hydrocortisone (or prednisolone) 
(Figures 5 and 7), repeat the original 5-day burst of 
steroids (Figure 7), and settle at a higher maintenance 
level of steroids. Although cyclosporin A does not permit 
much dose maneuverability, it has sometimes been pos-
sible to increase the amounts given despite the risk of 
nephrotoxicity. 
REJECTION AND ITS MODIFICATION 
To interpret much of the statistical information to be 
presented later in this review, it will be necessary to 
describe the features of homograft rejection as these have 
been perceived by the pathologist and surgeon. 
THE MORPHOLOGIC EVENTS OF REJECTION 
Despite treatment with any of the immunosuppressive 
regimens so far used, rejection of human hepatic homo-
grafts has been observed. A clear picture can be pieced 
together from studies of orthotopic liver transplantation 
in rats, dogs, pigs, baboons, and humans of the sequence 
of pathologic events which occur when a modified or 
unmodified recipient rejects a liver graft 010-113). 
In untreated members of all species (the principal 
observations have been in dogs), there is a quiescent 
phase of at least 2 or 3 days during which only rare small 
lymphocytes are found in the tissue spaces of the liver 
FIG. 5. Double-drug immunosuppres-
sion with cyclosporin A and steroids. The 
patient (OT 198) had a hepatoma, a-I-
antitrypsin deficiency, and chronic ac-
tive hepatitis. The reduction of the cy-
closporin A dosage after 4 days was be-
cause of the increasing azotemia. The 
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because of her small size. The temporary 
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placement with azathioprine between 
postoperative Da,'s 10 and 15 was be-
cause of probable cyclosporin nephrotox-
icity. The patient who was of B blood 
t'ipe was given the liver of an A donor. 
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FIG. 7. Deviation from standard steroid therapy in a patient (01' 219) whose perioperative condition was frail. The 5-day burst of postoperative 
steroids was begun several days postoperatively but had to be repeated when rejection supervened. Before operation, the patient had hl'patorenal 
syndrome and enc"phalopathy and he had been on a ventilator for more than 1 we"k. Because of defective clotting, efforts to place central venous 
lines before starting transplantation resulted in uncontrolled hemorrhage with the loss of 20 liters of blood. The subclavian and innominant 
vessels were explored through cervical and thoracotomy incisions, and the bleeding was mechanically controlled before transplantation was 
slarted. The blood loss from placpmenl of the vascular lines exceeded that incurred during transplantation. The patient survived because of 
prompt correction of the coagulation abnormalities. He is at home 5 months after transplantation. 
-- ---------------------------
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which remain normal except for nonspecific changes. 
However, during this period, large pyroninophilic cells 
start proliferating in the paracortical zones of the host 
lymph nodes. About 3 days after transplantation, lym-
phoid cells begin to leave portal vein tributaries randomly 
throughout the graft. The venous endothelium is sepa-
rated from the basement membrane, and fibrin collects 
in the subendothelial space. After passing through the 
vessel wall, lymphocytes accumulate in the portal tracts. 
Smaller numbers of lymphoid cells migrate through the 
walls of the central vein and the endothelial lining of 
sinusoids. These cells invade the space of Disse and some 
enter between hepatocytes. Immunoglobulins are rare in 
the cytoplasm of the infiltrating cells at this time. 
Associated with cellular infiltration, the cells of many 
sinusoids disintegrate, blood flow through the liver begins 
to decrease, and some centrilobular cells die. As the 
centrilobular necrosis progresses to midzonal necrosis, 
liver function becomes affected. Inspissated bile appears 
in surviving bile canaliculi and lipid droplets accumulate 
in the hepatocytes around the portal tract. Shortly before 
the death of the untreated recipient, foci of fibrinoid 
necrosis sometimes occur in the walls of small branches 
of the hepatic artery associated with deposition of im-
munoglobulin and complement in the intima and media. 
When rejection is mild, as in pigs (1l5), or is modified 
by immunosuppressive agents, as in dogs and humans 
(llO, 112-ll4, 116), destruction of hepatocytes ceases, 
cellular infiltration diminishes and may disappear, but 
the central part of the lobular reticulin framework often 
collapses. Accumulation of bile in surviving centrilobular 
hepatocytes and in bile canaliculi occurs; the cause of 
this severe cholestasis is not known and may be second-
ary to widespread loss or distortion of canalicular micro-
villi. An alternative possibility has been put forward by 
Myburgh et al. (Ill) who drew attention to the progres-
sive hypertrophy and dilatation of smooth endoplasmic 
reticulum in the centrilobular hepatocytes and suggested 
that these intracellular changes might be caused by hu-
moral antibody and result in disrupted cholesterol and 
bile salt metabolism with production of excess lithocho-
late. In some patients, the larger interlobular bile ducts 
disappear as modified rejection continues. This phenom-
enon is characterized by rapid and relentless rise in serum 
bilirubin (49-51, ll6). 
As rejection progresses, connecting bands of reticulin 
are often laid down between the central areas, subdivid-
ing the lobules. What triggers progression to hepatic 
fibrosis in some gr1!fts is unknown; excess lithocholate 
has been implicated (lll). In some patients, cirrhosis is 
produced. Another characteristic feature of chronic re-
jection is progressive thickening of the intima of the 
branches of the hepatic artery in the homograft. The 
intima contains fat-laden smooth muscle cells and mac-
rophages, and the lumen is narrowed or occluded. These 
arterial changes occur in many long-surviving liver hom-
ografts. The accumulation of immunoglobulins and com-
plement in the altered vessel wall has raised the possi-
bility that this damage is a late manifestation of rejection 
brought about by circulating antibody. Deposition of 
immunoglobulins is less striking in hepatic grafts than in 
transplant kidneys (1l7), prompting speculation that he-
patic rejection was more a phenomenon of cell-mediated 
immunity (as opposed to damage by circulating anti-
bodies) than has been thought to be the case with reject-
ing kidney grafts. 
Some histopathologic changes in liver homografts may 
be caused by hepatotoxic drugs, viral hepatitis, or other 
factors. However, a comparison of changes in human 
specimens with those in animal homografts emphasizes 
that the major alterations are immunologic in etiology. 
THE CLINICAL MANIFESTATIONS OF ACUTE 
REJECTION 
Rejection as defined by us (32) and Williams and CaIne 
(7) in patients treated with conventional immuno-
suppression also occurs during treatment with cyclos-
porin A and steroids. Many patients lose their appetites 
and become depressed. Fever, vague upper abdominal 
pain, and ascites are variable. By palpation, grafts are 
frequently swollen, hard, and mildly tender. Radioiso-
topes used for liver scanning are poorly concentrated, 
whether these depend upon parenchymal or reticuloen-
dothelial function. Elevations may occur in serum bili-
rubin, alkaline phosphatase, and transaminases. Failure 
of synthetic function is most readily detected by meas-
urements of prothrombin time. 
The various manifestations of rejection occur in differ-
ent combinations, to variable degrees, and at unpredict-
able times. The resulting patterns have been categorized 
as "anicteric," "indolent," and "crisis" (32). With a rejec-
tion crisis, jaundice can develop with astonishing rapid-
ity, usually just after or accompanied by major rises in 
transaminases. The insidious indolent rejections have 
been the most difficult to reverse. 
All patterns of graft deterioration are nonspecific. 
Proven alternative etiologies include ischemic injury, 
biliary obstruction, cholangitis, hepatitis (B virus, cyto-
megalovirus, adenovirus, herpes), and drug toxicity. Con-
sequently, diagnostic procedures, often including chol-
angiography and needle biopsy, must be considered if the 
postoperative evolution is not satisfactory. In the interim, 
steroid dosage is temporarily increased and returned to 
baseline if a diagnosis other than rejection is established. 
Clinical management is particularly difficult and fraught 
with error if good initial graft function was not achieved. 
A devastating complication of rejection, termed "septic 
hepatic gangrene," occurred in patients who were treated 
with azathioprine, ALG, and relatively low doses ofpred-
nisone. After days or weeks of slightly abnormal hepatic 
function, these patients developed massive hepatic ne-
crosis with extremely elevated serum transaminase activ-
ities and deterioration of other measures of hepatic func-
tion. Raging fevers, bacteremia, and disappearance on 
liver scans of large portions of hepatic parenchyma sig-
naled regional infarctions within the transplants. Kinking 
of lobar or segmental hepatic arteries was originally 
postulated to be responsible for this complication (5), but 
the most important factor is poorly controlled rejection 
(32). With diminution in total hepatic blood flow, as was 
documented in canine experiments by Groth et al. (31), 
invasion of the ischemic homograft by microorganisms 
from the adjacent intestinal tract is not surprising. 
Study of patients with septic hepatic gangrene and 
confirmatory observations by Brettschneider et al. (llB) 
after canine and porcine liver transplantations clarified 
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the interaction between rejection and homograft bacte-
rial colonization. In animal studies, the normally low 
incidence of positive cultures from liver tissue of dogs 
and pigs increased after sham operations. When an he-
patic ischemic injury was added by performance of sim-
ulated autotransplantation, all livers became contami-
nated, primarily with the same organisms concomitantly 
present in the upper intestine. Bacterial counts were 
somewhat lower if the common bile duct was left intact 
than when the duct was ligated and bile drainage restored 
by cholecystoenterostomy. The bacterial changes were 
more pronounced in liver homo grafts transplanted to 
unmodified or immunosuppressed animal recipients. 
Presumably, any ischemic or necrotic area can become 
a septic focus, particularly if the host is given immuno-
suppressive therapy and cannot respond normally to 
invading microorganisms. The spectrum of resulting in-
fections under conventional immunosuppression has 
been well studied (32, 119-121). Paradoxically, one of the 
most important ways to prevent nontreatable liver infec-
tion is to protect the graft with potent immunosuppres-
sion, especially during the early postoperative period. 
The second obvious step is to provide systematically 
designed antibiotic therapy intraoperatively and for sev-
eral days thereafter. 
Acute cellular rejection in grafts sampled by biopsy or 
at autopsy has been encountered many months or years 
after transplantation. Some patients were known to have 
discontinued their medications but others had been given 
unwise advice about lowering maintenance medications. 
Increased steroid therapy was given under such circum-
stances. 
CHRONIC REJECTION 
The diagnosis of chronic rejection was restricted to 
patients whose grafts had arterial intimal thickening, 
hepatic fibrosis, and other findings described previously. 
These findings are not necessarily time-related since they 
often develop within the first few months. Clinical man-
ifestations of chronic rejection were not much different 
from those of chronic liver failure from endstage disease 
of differing etiologies. Treatment with increased immu-
nosuppression was ineffective. 
SURVIVAL AFTER TRANSPLANTATION 
The introduction of cyclosporin A and steroids has had 
such a major influence upon results that patients have 
been divided into those treated before and after this 
event. By so doing, it is possible to reexamine several 
factors whose significance was previously unclear. 
PRECYCLOSPORIN ERA (1963 TO 1979) 
Between 1963 and the end of 1979, 170 patients had 
liver replacement. In previous publications, the identifi-
cation of individual recipients by orthotopic transplan-
tation (OT) numbers made it possible for the interested 
reader to follow their progress from report to report. The 
same code numbers will be used throughout this review. 
In past reports (45, 80, 107), the first 170 recipients 
were divided into the three successive series summarized 
in Table 6 and Figure 8. In the first, second, and third of 
these consecutive groups, I-year survival was 28.8, 50, 
and 34.5%. 
Of the 56 recipients who survived the first postopera-
tive year, 23 died at the times shown in Table 6. Although 
13 of 23 late deaths were in the second postoperative 
year, deaths occurred as late as 6 years. Of the original 
170 patients, 33 (19.4%) are alive after follow-ups of 21/2 
to 121/2 years. Twenty have survived for more than 5 
years and four are into the second postoperative decade. 
There was an almost equal division in the total period 
of 1963 to 1979 between adult (:::,:,:19 years) and pediatric 
(:s18 years) recipients. From the sixth month onward, 
the younger patients had about a 10% survival advantage 
(Figure 9). 
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TABLE 6. LATE DEATHS IN 170 PATIENTS DURIl'G PRECYCLOSPORIN A ERA (1963-1979) 
No. Alive after Died after Time of late death to Alive Years follow-up 1 year 1 year nearest postop month now of survivors 
Series 1 111 31 (28.8%) 18 12, 13, 13, 13, 14, 16, 17.20,20,21 13 6','2-121/2 
25,26,28,30,36,41,54.72 
Series 2 :>0 15 (50%) 4 17, 23, 49, 56 11 4V2-5'Y. 
Series 3 29 10 (34.5%) 13 9 2'/2-4'/, 
--------------- --------------------_ .. _-_._-_. __ ._._---
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Table 7 summarizes the results in the Cambridge-
King's College trials from 1968 through early 1980 (53, 
1.22). In this series, 22 (23.7%) of the first 93 recipients 
lIved for at least 1 year, with 11 subsequent deaths during 
the second to sixth years; the 11 survivors had been 
followed for 1 to 6 years. The better I-year survival in 
the American compared to the English trial (33 us. 24%) 
was partly illusory since CaIne and Williams accepted for 
surgery few pediatric patients with whom (Figure 9) our 
best results were obtained in those years. 
Our results in the pediatric age group after transplan-
tation for different indications are given in Table 8. 
Similar information for adult recipients is provided in 
Table 9. 
CYCLOSPORIN ERA (1980 TO 1982) 
The longest follow-ups for our patients treated with 
cyclosporin A and steroids are only 2 VI years. During the 
TABLE 7. ACTUAL 1-YEAR SURVIVAL" IN CAMBRIDGE/KING'S 
COLLEGE SERIES OF 93 CASES (1968 TO FEBRUARY, 1980) 
No. 1 week (j months I year 
9.1 77 (82.8' ,) 22 (2:!.7%) 
" Information from (122). Of the 22 one-year survivors, II had subsequently 
di"d from 1 to more than::; years postoperatively. The other II were living in 
their second to sixth postoperative year. An actuarial projection of this data 
beyond 1 year is depicted in Figure 10. 
TABLE 8. INDICATIONS FOR TRANSPLANTATION AND SURVIVAL IK 
PEDIATRIC PATlEKTS (::S18 YEARS) FROM 1963 THROUGH 1979 
(PRECYCLOSPORIN A) 
Survival (months) 
No. 
>1 >2 >6 >12 Nowll 
Biliary atresia 51 37 27 16 14 7 
(73%) (53%) (31%) (27%) (14%) 
Inborn meta- 13b 12 11 8 8 6 
bolic errors (92%) (85%) (62%) (62%) (46nc) 
Chronic aggres- 13 11 10 7 5 :3 
sive hepatitis (85%) (77%) (54%) (:38%) (23%) 
Hepatoma 3c 3 3 2 2 0 
Neonatal hepa- 2 0 
titis 
Congenital he- 2 
patic fibrosis 
Secondary bili- 2" 2 2 2 2 
ary cirrhosis 
86 67 55 37 33 18 
(78%) (64%) (43%) (38%) (21%) 
" Follow-ups for living patients are 21,1, to 121,1, years. 
b Inborn errors 
a-I-antitrypsin deficiency 9 
Wilson's disease 2 
Tyrosinemia 
Type IV glycogen storage disease 
13 
'Five other patients had incidental malignancies (4 hepatomas and 
1 hepatoblastoma) in their excised livers. The principal diagnoses in 
these five cases were biliary atresia (3 examples), a-I-antitrypsin defi-
ciency (1 example), and congenital tyrosinemia (1 example). The diag-
nosis of the neoplastic change was known in advance only in 2 of the 5 
cases. 
d Secondary to trauma or choledochal cyst (one each). 
TABLE 9. INDICATIONS FOR TRANSPLANTATION AND SURVIVAL IN 
AnCLT PATIENTS (2:19 YEARS) FROM 196:3 THROUGH 1979 
(PRECYCLOSPORIN A) 
Survival (months) 
No. ---------- ----
>1 >2 >6 >12 Now" 
Chronic aggres- :3.3 21 17 14 11 7 
sive hepatitis (64%) (52%) (429(-) (:33'; ) (21';) 
Alcoholic cir- 15 8 5 4 4 :3 
rhosis (5:3%) (:3:3'0 (27%) (27%) (20%) 
Primary malig- 15" 9 7 4 3 1 
nancy (60'Y) E4irI~F (27%) (20%) (7%) 
Sclerosing cho- 7 7 4 2 2 0 
langitis 
Primary biliary Ii a :3 2 
cirrhosis 
a-I-antitrypsin 2 0 0 0 
deficiency 
Secondary bili- 2' 
ary cirrhosis 
Hemochromato- 0 0 0 0 
SIS 
Protoporphyria 0 0 0 0 0 
Budd-Chiari I 
svndrome 
Acute hepatitis 0 0 0 
B 
84 63 40 28 2:3 14 
(6:3%) (48o/r) (:33%) (27%) (17%) 
" Follow-ups for living patients are 2\1, to 81/2 years. 
/, Seven hepatomas, 5 duct cell carcinomas (Klatskin), I cholangio-
carcinoma, 1 hemangioendothelialsarcoma, and 1 unclassified sarcoma. 
, One example each of possible duct hypoplasia and choledochal 
cyst; both patients had had multiple operations. 
first 9 months of 1980, 14 patients entered into this trial 
at the University of Colorado (l08); 2 died during the 
operation, and 1 died after 19 days. The other 11 patients 
survived for more than 1 year. Eight are alive after 21 to 
28 months. The 1-year survival of 78.6% could have 
represented a sampling accident. However, at the Uni-
versity Health Center of Pittsburgh, 26 patients were 
treated in 1981. Five died in the first postoperative 
month, and additional deaths occurred in the second, 
third, and fourth months. With follow-ups of 6 months to 
more than 1 year, the remaining 18 (69.29'd recipients are 
alive and at home; none has poor hepatic function. 
The pattern of predominantly early mortality seen in 
1980 and 1981 has continued into 1982. Of the first 27 
recipients treated in 1982, I) died. Six, one, and one of 
these deaths were in the first, second, and third postop-
erative months, respectively. 
It is too early to assess the rate at which late deaths 
will occur, since only 18 patients treated with cyclosporin 
A have reached or passed the I-year mark. Of these, 
three died in their thirteenth, sixteenth, and twentieth 
postoperative months for reasons that will be considered 
in the next section. 
The actuarial survival calculated from the cases in the 
cyclosporin era studied to date is shown in Figure 10. In 
comparison to our previous experience in the precyclo-
sporin era and in comparison to the Cambridge-King's 
College compilation, survival has more than doubled. 
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FIG. 10. The actuarial survival of patients treated with cyclosporin 
A and low-dose steroids compared to the actual I-year survival obtained 
under conventional immunosuppression by us (azathioprine) and the 
workers at Cambridge. The data for the Cambridge curve were obtained 
from published reports (5:1, 122). 
The results calculated for the first 12 postoperative 
months have not been different in adults and children 
(Figure 11). A breakdown of results according to original 
disease in the pediatric and adult cases is provided in 
Tables 10 and II. 
The influence of cyclosporin A upon survival in the 
Cambridge-King's College trials has not been clearly 
defined, because the drug has not been regularly used 
and because it was started late in most cases after an 
initial course of azathioprine and steroids. Nevertheless, 
improved results have been attributed by CaIne et al. 
(53) to better immunosuppression. 
CAUSES OF MORTALITY 
PRECYCLOSPORIN ERA 
Early Death. The appalling early mortality after liver 
transplantation has prompted exhaustive clinical-patho-
logic analyses of our failed cases. Using the OT code 
numbers of the patients, the results have been reported 
in such a way that individual assessment of almost every 
early death in the first 170 cases can be made by the 
interested reader (43, 45, 80). Mortality figures included 
the use of grafts damaged by ischemia, massive operative 
hemorrhage, thrombosis of the reconstituted homograft 
blood supply, intraoperative cerebral air embolism (44), 
unsuspected recipient abnormalities (such as prior 
thrombosis of the portal vein), hopeless anatomical sit-
uations created by multiple previous operations, irre-
versible preexisting debilitation, and (above all) defective 
biliary tract reconstruction. 
With or without such factors, overwhelming infection 
was frequently a terminal event. At autopsy, histopath-
ologic findings of acute rejection were found in 10 to 15o/c 
of cases, prompting speculation that over immuno-
suppression, especially with prednisone, may have been 
responsible for unnecessary deaths (43). 
When serial biopsies were obtained in later cases (45, 
80), this simplistic view had to be revised. Many biopsies 
contained unmistakable findings of rejection for which 
the appropriate response had been more steroids. After 
death caused by infection, the findings of rejection were 
absent. The conclusion was reached that even after a 
perfect operation, the unacceptable acute mortality 
would remain until improved immunosuppression be-
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FIG. 11. The I-year actuarial survival of adults vs. children after liver 
transplantation under immunosuppression with cyclosporin A and ste-
roids. 
TABLE 10. INDICATIONS FOR TRANSPLANTATION IN PEDIATRIC 
PATIENTS E~1U YEARS) FROM Mm-1980 TO MAY, 1982 
(CYCLOSPORIN ERA). FOLLOW-UPS FOR SURVIVORS ARE 1-21 
MONTHS 
Biliary atresia" 
a-I-antitrypsin deficienc/ 
Chronic aggressive hepatitis 
Byler's disease" 
Secondary biliary cirrhosis" 
Budd-Chiari syndrome 
Neonatal hepat.itis 
Subacute Wilson's disease" 
Tyrosinemia" 
Type I glycogen storage disease" 
Sea-blue histiocyte syndrome" 
a Two had Alagille's syndrome. 
No. Living 
11 8 
4 2 
2 2 
2 
0 
0 
26 18 
(70(k) 
" Inborn errors of metabolism. The children with tyrosinemia and 
sea-blue histiocyte syndrome had incidental hepatomas in their cir-
rhotic livers. 
" Diagnosis equivocal in one case. 
d Choledochal cyst with multiple operations. 
TABLE 11. INDICATIONS FOR TRANSPLANTATION IN ADCLT PATIENTS 
E~19 YEARS) FROM MARCH 1, 1980 TO MAY 1, 1982 (CYCLOSPORIN 
ERA). FOLLOW-UP FOR SURVIVORS WAS 1-27 MONTHS 
-------------------------------------
Chronic aggressive hepatitis 
Malignancy" 
Primary biliary cirrhosis 
Secondary biliary cirrhosis 
2 trauma 
1 Caroli 
1 choledochal cyst 
Sclerosing cholangitis 
a-I-antitrypsin deficiency 
Budd-Chiari syndrome 
Adenomatosis" 
No. 
14 
9 
6 
4 
3 
2 
2 
Living 
9 
I 
5 
2 
2 
41 28 
(68%\ 
" One patient in each group had previous (1 and 4'/2 years earlier) 
right hepatic trisegmentectomy. At transplantation, the regenerated 
Ie ft.-lateral segment was replaced with a whole liver. 
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came available. Both nonimmunologic and immunologic 
complications have continued to cause early deaths in 
the cyclosporin era albeit at a reduced rate. 
Deaths After 1 Year. Assessment of the reasons for 
late death in older cases may help to predict the spectrum 
of problems which can be expected in future patients. 
The causes of mortality after 1 year in patients treated 
with conventional immunosuppression are listed in Table 
12. Recurrent liver failure was responsible for death in :% 
of 23 patients, if the four who died after attempted 
retransplantation are included. In three patients, the 
main mortality factor was recurrence of malignancy. One 
of the late deaths was caused by chicken pox hepatitis 
during an epidemic on the transplantation ward. The 
patient (OT 112) whose death was classified under self-
abuse was an alcoholic, drug abuser, and derelict who 
resumed the same life style after transplantation. Fifty-
six months after transplantation, he was found uncon-
scious in a ditch in Florida and died of pneumonitis. 
The dominant pathologic diagnoses of the 24 first or 
second grafts which functioned chronically in these 23 
patients are listed in Table 13. Chronic rejection was the 
TABLE 12. CAUSES OF 23 DEATHS" AFTER 1 YEAR ot' PATIENTS 
TREATED WITH AZATHIOPRINE (OR CYCLOPHOSPHAMIDE), 
PREDNISONE, AND ALG 
Cause of death 
Predominant liver failure 
Liver failure plus sepsis 
Early after retransplantation 
Recurrent cancer 
Predominant sepsis 
Self-abuse 
Total 
No. 
8 
5 
4" 
3 
2 
23 
" Deaths were usually caused by multiple problems, but only the 
single most important factors are listed. 
h Infection invariably contributed to death after retransplantation, 
In addition, two patients had lethal technical complications and two 
more had rejection. 
TABLE 13. PRINCIPAL PATHOLOGIC CHANGES IN 24 LIVER GRAFTS 
THAT HAD FUNCTIONED UNDER CONVENTIONAL 
IMMUNOSUPPRESSION FOR 339 TO 2,190 DAYS BEt'ORE THE DEATH 
OF THE PATIENT." IN 5 OF THE 24 GRAt'TS, Two DIAGNOSES WERE 
GIVEN 
Pathologic changes 
Chronic rejection 
Biliary obstruction 
Recurrent cancer 
Chronic hepatitis 
Portal vein thrombosis 
Chronic cholangitis 
Chicken pox, hepatitis with necrosis 
Early alcoholic hepatitis 
Diffuse fatty changes with centrilobular necrosis 
Total 
No. 
11 
6 
4 
2 
2 
1 
29 
" These 24 grafts were from the 23 patients who died after 1 year 
(Table 12). Seven of the 23 patients were given two livers, but chronic 
function (682 plus 403 days) was obtained from both organs in only one 
case (OT 103); in the other six, the pathologic changes are tabulated 
only for the long-surviving grafts. Most of the specimens were obtained 
at autopsy, but a few were from surgical or closed biopsies. 
most common final diagnosis, followed by biliary obstruc-
tion and recurrent cancer. There were two examples each 
of chronic hepatitis and portal vein thrombosis. 
These findings differ from those reported by CaIne et 
al. (53) in 11 patients who died after 1 year; recurrent 
carcinoma was the main homograft abnormality in five 
patients. In the other six grafts, there was biliary sludge 
and cholangitis. Chronic rejection was not mentioned. 
Our findings suggest that ongoing problems with immu-
nologic control will continue to take a gradual toll long 
after successful transplantation, whereas interpretation 
of the pathologic findings in the English recipients is 
different. Clarification of this divergence of observations 
will be important. 
CYCLOSPORIN ERA 
Twenty-two of the 67 patients treated in 1980 to 1982 
died, Three deaths were after 1 year, and the other 19 
were early. 
Early Death. Fourteen of 19 early deaths, including 
two on the operating table, occurred in the first postop-
erative month, In the second, third, and fourth postop-
erative months, there were 1, 1, and 2 more death(s), 
respectively (Table 14). 
Eight deaths were directly attributable to preexisting 
anatomic conditions including multiple previous opera-
tions (OT 178), earlier portacaval shunt (OT 180), and 
right-to-left pulmonary shunts secondary to the liver 
disease (systemic arterial p02 was 30 mm Hg) which did 
not subsequently close (OT 203). However, the most 
important abnormalities were ill liver blood supply or the 
vena cava (OT 217, 220, 228, 232, 233) which had not 
been diagnosed preoperatively. At operation, it was not 
possible to vascularize adequately homo grafts in 4 of 
these latter 5 recipients. In the fourth (OT 233), the 
superior vena cava was discovered at autopsy to have 
been replaced by two innominate veins which descended 
into the abdomen and emptied into the inferior vena 
cava below the renal veins. During the vena caval cross-
clamping of the anhepatic phase of transplantation, the 
child developed an acute superior vena caval syndrome 
with irreversible brain injury. 
Eight early deaths were technical and thus avoidable, 
including the use of inadequately preserved grafts (OT 
185 to 188), hepatic artery thrombosis (OT 183, 225), and 
complications of biliary tract reconstruction (OT 201, 
208). Problems in preservation were encountered in the 
first four cases at a new institution. 
Deaths After 1 Year. Patients died late (Table 14) of 
recurrent Budd-Chiari syndrome (OT 174), recurrent 
duct cell carcinoma (OT 176), and after retransplantation 
after a primary graft was chronically rejected (OT 181), 
THE POSSIBILITY OF RETRANSPLANTATION 
In assessing ways of reducing patient mortality, it was 
obvious almost from the beginning that aggressive at-
tempts at retransplantation offered the only chance of 
survival for many patients whose first grafts failed either 
early or late. Such efforts, which have been made in 27 
patients (2 of the 27 also were given third grafts) since 
1968 (Figure 1), usually have born bitter fruit. The few 
successes that have been achieved have served as an 
important stimulus for further trials. 
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OT 
174 
176 
178 
180 
181 
183 
185 
186 
187 
188 
196 
201 
203 
208 
215 
216 
217 
220 
225 
228 
232 
233 
Age 
20 
33 
37 
40 
16 
8 
56 
17 
37 
46 
36 
4 
18 
42 
39 
2 
44 
8 
44 
3 
6 
2% 
Sex 
F 
F 
M 
M 
F 
F 
M 
F 
F 
M 
F 
M 
M 
M 
F 
F 
M 
F 
M 
M 
F 
F 
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TABLE 14. MAJOR CAUSES OF 22 DEATHS IN CYCLOSPORIN ERA 
Pathology before transplant 
Budd-Chiari syndrome, portacaval shunt 
Sclerosing cholangitis, duct cell carcinoma 
Secondary biliary cirrhosis, gunshot wound 
to liver 
Sclerosing cholangitis, portacaval shunt 
Budd-Chiari syndrome 
Byler's disease 
Klatskin's tumor 
Secondary biliary cirrhosis, Caroli's disease 
Chronic aggressive hepatitis, portacaval 
shunt 
Chronic aggressive hepatitis 
Chronic aggressive hepatitis 
a-I-antitrypsin deficiency disease 
a-I-antitrypsin deficiency disease, exten-
sive pulmonary A-V shunt 
Chronic aggressive hepatitis, a-I-antitryp-
sin deficiency disease, primary biliary 
cirrhosis 
Primary biliary cirrhosis 
Biliary atresia, Kasai operation 
Chronic aggressive hepatitis, splenectomy, 
portal vein hypoplasia" 
Secondary biliary cirrhosis, choledochal 
cyst, portal vein thrombosis" 
a-I-antitrypsin deficiency disease 
Alagille's syndrome, absent hepatic ar-
tery", hypoplastic portal vein" 
Biliary atresia, Kasai operation, absent in-
ferior vena cava", malrotation" 
Biliary atresia, Kasai operation, absent su-
perior vena cava with innominate drain-
age into inferior vena cava" 
Major causes of death 
Recurrent Budd-Chiari syndrome, liver 
failure, sepsis 
Recurrent duct cell cancer 
Operative 
Operative 
1st graft: chronic rejection 
2nd graft: acute rejection 
3rd graft:, liver failure, renal failure 
Hepatic artery thrombosis 
Graft necrosis, sepsis 
Graft necrosis, sepsis, bile leakage 
Graft necrosis 
Graft necrosis, sepsis 
Systemic aspergillosis 
Hemorrhage during exploration of intra-
hepatic abscess and mycotic aneurysm 
1st graft: graft hypoxia due t.o pulmonary 
A-V shunt 
2nd graft: graft hypoxia; rejection 
3rd graft: graft hypoxia; cerebral hemor-
rhage 
Hemorrhage from hepatic artery, bile duct 
fistula 
Rejection; sepsis due to duodenal stump 
leakage after total gastrectomy for stress 
ulcer hemorrhage 
Chronic rejection, liver failure, sepsis 
Operative 
1st graft: graft necrosis 
2nd graft: cerebral hemorrhage 
1st graft: rejection, hepatic artery throm-
bosis 
2nd graft: rejection, sepsis 
Graft necrosis 
Diffuse clotting in graft 
Perioperative brain death 
" Anomalies or abnormalities not known before operation. 
629 
Postoperative 
month of 
death 
16 
13 
1 
20 
1 
1 
1 
2 
4 
3 
3 
4 
The attempts at retransplantation in 27 patients are 
summarized in Table 15. Eighteen of 27 second trans-
plantations were within the first 3 months, 3 were be-
tween 3 and 12 months, and 6 were after 12V2 to 29 
months. 
the primary graft had developed a huge fungus abscess; 
in the second patient, the first graft had been rejected. 
Extended subsequent survival occasionally was 
achieved with early and later retransplantation_ The fate 
of six patients whose lives were significantly prolonged is 
summarized in Table 16. Much of life for the first four 
recipients was a nightmare of morbidity because of the 
combination of high steroid needs and slowly failing graft 
function. However, the two patients who had successful 
retransplantation in the cyclosporin A era, 1 and 3 weeks 
after primary grafting, have had perfect results and are 
at home 6 and 12 months later on daily prednisone doses 
of 5 and 15 mg per day, respectively_ In the first patient, 
The performance of retransplantation has sometimes 
been surprisingly easy. The procedure has been greatly 
simplified by retaining cuffs from the suprahepatic and 
infrahepatic vena cava and from the portal vein of the 
first graft. Usually, it has been necessary to perform the 
arterial anastomosis proximal to the previous site. 
THE INFLUENCE OF ORIGINAL DISEASE UPON 
RESULTS 
Evaluation of the influence on survival of preexisting 
hepatic disease is complicated by the fact that many 
patients have more than one diagnosis (Table 17). Ten 
(14_9%) of our last 67 patients had two coexisting hepatic 
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TABLE 1.5. ATTEMPT AT RETltANSPLANTATION IN 27 PATIENTS'" h 
Conventional 
immuno-
suppression 
Cyclosporin-
Steroids 
No. 
21 
6 
Months between first 
and second transplanta. Months survival after sec-
tion ond transplantation 
<1 X 9 patients, <1 X 11 patients, I, I, 
1'/4, 2, 2V" 3, 3'/" 5'/" 1 Y3, 1'12, 1%, 2, 6, 12, 
6, 12'1" 16';:', 221f2, 27, 13, 16 
29 
<1 X 5 patients, 19 <1 X 3 patients, 3'1" 
6",12' 
a Two of the 27 had third transplantations, 1 and 7'/, weeks after 
second transplantation had failed. 
h One patient had a chimpanzee heterograft on the second occasion, 
, Alive, 
TABLE 16. TIME OF RETRANSPLANTATION IN SIX PATIENTS WHO 
SUBSEQUENTLY LIVED FOR >6 MONTHS 
OTNo, Duration of first graft Survival in months after second graft 
16 2 months 11 
98 5'/. weeks 16 
103 OO~/O months 13 
156 2 weeks 6 
191 3 weeks 12" 
209 1 week 6" 
" In cyclosporin series, both alive. 
TABLE 17. PATIENTS IN CYCLOSPORIN A SERIES (67 CASES) WITH 
MULTIPLE DIAGNOSES 
aT No, Main diagnosis Other diagnosis 
176 Cholangiocarcinoma Sclerosing cholangitis 
188 Chronic aggressive hepa- Heterozygous a-I-anti-
titis trypsin disease 
198 Hepatoma a-I-antitrypsin disease, 
chronic aggressive 
hepatitis 
206 Tyrosinemia Hepatoma, diagnosed at 
previous operation 
208 Chronic aggressive hepa- a-I-antitrypsin disease 
titis 
218 Type I glycogen storage Multiple hepatic adeno-
disease mas 
222 Sea-blue histiocyte syn- Hepatoma, diagnosed at 
drome previous operation 
225 a-I-antitrypsin disease Hemachromatosis 
(Pi ZZ) 
227 Hepatoma Chronic aggressive hepa-
titis 
234 Hepatoma Chronic aggressive hepa-
titis 
diseases; however, in most of our analyses (Table 8 to 
ll), only the most important diagnosis was tabulated. 
No disease for which transplantation has been used 
can be categorically excluded for further trials. This can 
be appreciated by examination of results with different 
kinds of disease in pediatric and adult patients before 
and after the introduction of cyclosporin A (Tables 8 to 
ll). 
Nevertheless, special problems can be expected in 
treating some hepatic diseases. In the past, some patients 
with biliary atresia died because of unexpected anomalies 
which jeopardized performance of a technically satisfac-
tory transplantation (32); specific examples are listed in 
Table 14. 
Noncompliance may be a problem in patients treated 
for Laennec's cirrhosis. Of our first nine patients with 
alcoholic cirrhosis, eight died too soon to evaluate this 
potential problem (123). There were several subsequent 
successes (Table 9); only one recipient returned to toxic 
drinking. 
THE SPECIAL PROBLEM OF HEPATIC MALIGNANCY 
The possibility that immunosuppression may acceler-
ate metastatic tumor growth has been recognized (32). 
Evaluations of transplantation in treating hepatic malig-
nancies were made in 1981 by Iwatsuki et a1. (124) and 
by CaIne (122). Although recurrent disease exceeded 50% 
in both series, the results did not allow definitive rec-
ommendations about continuation of these efforts. 
Our case material has been divided into three groups. 
In the first category were three children whose livers 
contained malignant tumors (2 hepatocellular cancers, 1 
hepatoblastoma) that had not been suspected preopera-
tively (Table 18). The two recipients who survived op-
eration have no evidence of recurrence after 4V4 to 12V2 
years. These observations suggest that malignancies can 
be cured by liver replacement. 
In the second category were eight patients, all treated 
early in our experience, who died less than 1 month after 
liver replacement for hepatic or duct cell cancer (Table 
19). From this case collection, it was possible to deter-
mine by autopsy studies the frequency with which extra-
hepatic tumor spread had been missed in preoperative 
evaluation. Only 1 of the 8 recipients had metastases. 
Twenty-two additional patients, including one (OT 
176) whose neoplastic lesion was missed at the initial 
pathologic examination, lived long enough to evaluate 
the influence of transplantation upon the malignancy 
(Table 20). The first 12 were treated in the precyclosporin 
era; nine recipients developed metastases. A tenth pa-
tient with an unclassified sarcoma had extrahepatic me-
tastases at transplantation, and she is well 5% years later 
with no clinical evidence of advancing disease. Five pa-
tients survived for longer than 1 year; even for those who 
eventually died of metastases, the extension of useful life 
seemed to be worthwhile. 
Ten more patients have been treated in the cyclosporin 
era (Table 20). Three had duct cell carcinomas (one with 
sclerosing cholangitis); one of whom (OT 185) died early 
without evidence of residual cancer. The second patient 
(OT 176) died of metastatic cholangiocarcinoma after 1 
year. The third (OT 200) is alive in the ninth postopera-
tive month and has metastases. All patients with hepa-
tocellular carcinoma are alive. The tumors were enor-
mous in three cases. In the other four, the lesions were 
smaller but could not be resected with conventional 
techniques because of coexisting cirrhosis. It seems likely 
that selected patients with hepatic or possibly biliary 
duct malignancies can be effectively treated with trans-
plantation; however, no patient with duct cell carcinoma 
has ever been cured (53, 122, 124). The prospects may be 
more favorable for young patients whose hepatocellular 
cancers could be treated with conventional partial hep-
atectomy were it not for coexisting cirrhosis. 
Heroic efforts may be justifiable for patients with the 
recently described "fibrolamellar hepatoma" which is 
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TABLE 18. PATIENTS TREATED FOR ENDSTAGE BENIGN LIVER DISEASE WHOSE REMOVED LIVERS CONTAINED AN UNSUSPECTED PRIMARY 
LIVER MALIGNANCY AS WELL. ALL WERE TREATED WITH AZATHIOPRINE, PREDNISONE, AND ALG 
Incidentally found liver ma- Survival 
Tumor recur-
Patient Age Sex Primary indication for transplant lignancy rence (yr) 
F Biliary atresia Hepatoma Alive 12 V2 years No 01' 33 3 
OT80 7 F Biliary atresia Hepatoma 
Operative death 
5 F n-i-antitrypsin deficiency Hepatoblastoma Alive at 41/2 years No OT 142 
TABLE 19. PATIENTS WITH KNOWN PRIMARY LIVER MALIGNANCY WHOSE EARLY DEATH AFTER TRANSPLANTATION PRECLUDED 
OBSERVATIONS OF THE COURSE OF THE MALIGNANCY. ALL WERE TREATED WITH CONVENTIONAL IMMUNOSUPPRESSION BEFORE 1975 
Age Sex Diagnosis Survival (days) Metastases at autopsy and 10- Main cause of death Patient (yr) cations 
OT2 48 M Hepatoma, cirrhosis 
01'3 68 M Bile duct carcinoma 
(Klatskin's tumor) 
OT4 52 M Cholangiocarcinoma 
cirrhosis 
OT5 29 F Hepatoma 
01'6 29 M Hepatoma 
OT7 24 F Hepatoma 
01'25 45 M Hepatoma 
01'79 60 M Bile duct carcinoma 
(Klatskin's tumor) 
characterized by indolent primary growth and late me-
tastases (125, 126). Three of our last 10 patients with 
hepatic malignancy have had this diagnosis. In all three, 
the tumors were massive. In one patient who was treated 
more than 2 years ago (OT 172), a large tumor thrombus 
originating in a hepatic vein was extracted at operation 
from the vena cava and right atrium. He is tumor-free. A 
second patient, who also is tumor-free after almost 1 year 
(OT 194), had complete obstruction of the portal vein by 
tumor. A third patient treated 2 months ago (OT 231) 
developed recurrence in the residual lateral segment after 
a right trisegmentectomy 41/2 years earlier. The tumor-
laden residual segment was replaced with a new liver 
with a satisfactory result thus far. 
At the moment, the prospects for cure seem bleak for 
patients with duct cell carcinomas, and scarcely better 
for those with unresectable conventional hepatocellular 
carcinomas. Patients with smaller malignancies in livers 
with other diseases, or those with fibrolamellar hepato-
mas may be more susceptible to treatment. 
RECURRENCE OF OTHER HEPATIC DISEASES 
In pediatric recipients (Tables 8 and 10), recurrence of 
nonneoplastic hepatic disease has not been observed. A 
special feature of transplantation in the younger age 
group has been the metabolic "cure" of at least five and 
possibly six so-called inborn errors (Tables 8 and 10) 
(126-131). With cyclosporin A, the prospects of using 
transplantation to treat children with a variety of dis-
eases has been heightened because chronic high-dose 
steroid therapy can be avoided (132). 
That the original disease can be recapitulated in hom-
ografts was demonstrated in adult recipients. Two pa-
tients with Australia antigenemia and chronic aggressive 
hepatitis redeveloped their original disease and died 
(133). Other patients with recurrent or newly developing 
21 No Pulmonary emboli, sepsis 
8 No Sepsis, pulmonary emboli, 
gastrointestinal bleeding 
5 Bone, lung, kidney, Pulmonary emboli, hepatic 
lymph nodes failure, pulmonary edema 
24 No Sepsis, bile peritonitis, hepatic 
failure 
7 No Hepatic failure, sepsis 
17 No Pneumonitis 
29 No Bile peritonitis, sepsis, hepatic 
failure 
19 No Hepatic failure due to biliary 
obstruction 
Australian antigenemia have lived for as long as 8 years 
with the carrier state. It has been our policy to treat 
HBsAG positive transplant recipients with hyperimmune 
globulin postoperatively. Antigenemia has returned in 
every case, sometimes after becoming undetectable for 
months. With such treatmenl, Johnson et al. reported 
permanent antigen clearing in a patient (134). 
Recurrent primary biliary cirrhosis (135) as described 
in the English series was not seen in five grafts studied at 
autopsy after a few days to more than 6 months, and five 
patients still living have had no evidence of recurrence in 
spite of the reappearance of antimiochondrial antibodies 
in the longest survivors (21/4 and almost 4 years). 
We have treated three patients for the Budd-Chiari 
syndrome. One (OT 174) developed the same disease in 
the graft and died after 15 months. The terminal course 
of this patient was triggered by unwise discontinuance of 
anticoagulant therapy in preparation for a closed liver 
biopsy. CaIne et al. (53) reported a similar occurrence. 
THE INFLUENCE OF PREVIOUS OPERATIONS 
The technical problems engendered by prior surgery 
have been so great that the Cambridge-King's College 
Team consider multiple earlier operations as a relative 
contraindication to transplantation. However, the major-
ity of candidates evaluated by us and the English workers 
have had previous operations. The influence ofthis factor 
was evaluated in the first 40 patients treated with cy-
closporin A and prednisone (Table 21) in whom the 
results were more analyzable than in our earlier cases. 
Fourteen of 40 recipients had major procedures on 
portal triad structures (Table 21) including six portal-
systemic shunts and five biliary duct reconstructions. 
The risk of death in the first postoperative month was 
double that in patients with lesser or no earlier opera-
tions. There were two operative deaths (OT 176 and 180) 
(Table 21) including one that occurred while trying to 
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TABLE 20. PATIENTS WITH PRIMARY HEPATIC MALIGNANCY. THE DIAGNOSIS OF NEOPLASIA WAS KNOWN IN ADVANCE OF 
TRANSPLANTATION EXCEPT IN 01' 176. POSTOPERATIVE SURVIVAL WAS AT LEAST 2 MONTHS FOR ALL BUT ONE PATIENT 
Patient Age Sex Diagnosis Survival Malignancy (yr) (months) Metastases factor in 
death 
Precyclosporin Era 
01'8 1'/," F Hepatocellular cancer >13 Brains, lungs, liver other abdominal or- Main 
gans 
01' 14 16 F Hepatocellular cancer >14 Diaphragm, retroperitoneal space, liver, Major 
pancreas 
01' 15 4.3 M Hepatocellular cancer, cirrhosis >11 Lungs, liver, diaphragm Main 
01'2:3 15 M Hepatocellular cancer >4 Br~inI lungs, liver, retroperitoneal space Main 
01'26 11 F Biliary atresia, hepatocellular cancer >2 Lung None 
01'45 53 M Hemangioendothelial sarcoma >2 Brain, lungs, liver, spleen, pericardium, Main 
peritoneum, stomach, pancreas, kidney 
01'78 48 M Bile duct carcinoma (Klatskin's tumor) >24 Liver, bile duct at reoperation. No au- Main 
topsy 
01'90 41 M Bile duct carcinoma (Klatskin's tumor) >54 Bile duct, liver, duodenum at reoperation Main 
No autopsy 
01' 102 51 F Bile duct carcinoma (Klatskin's tumor) >2 None None 
01'111 9 F Tyrosinemia, hepatocellular cancer >3 Microscopic metastasis in the lung and Minor 
paraaortic lymph nodes at autopsy 
01' 114 27 F Sarcoma (undetermined cell type) of liver >68 (Alive) Grossly fine intraabdominal and pulmo- Alive 
invading diaphragm, metastasis to right nary metastases at time of transplan-
lung and peritoneum tation which have been quiescent for 
5Y" years 
01' 121 32 F Hepatocellular cancer >5 None None 
Cyclosporin Era 
01' 172 24 M Hepatocellular cancer" >27 None Alive 
01' 176 33 F Sclerosing cholangitis, duct cell carci- >12 Liver, duct, peritoneum Main 
nomab 
01' 185 56 M Duct cell carcinoma (Klatskin's tumor) >'/2 None None 
01' 194 26 M Hepatocellular cancer" >11 None Alive 
01' 198 47 F a-I-antitrypsin disease, cirrhosis, hepato- >9 None Alive 
cellular cancer 
01'200 27 M Duct cell carcinoma (Klatskin's tumor) >8 Liver, operative wound Alive 
01' 206 2 F Tyrosinemia, hepatocellular cancer >7 None Alive 
01' 227 53 M Cirrhosis, hepatocellular cancer >.3 None Alive 
01' 231 23 F Hepatocellular cancer", previous right tri- >2 None Alive 
segmentectomy 
01' 234 24 F Hepatocellular cancer, cirrhosis >1 None Alive 
" Fibrolamellar. 
h Diagnosis of cancer missed in surgical specimen, but diagnosed at surgical margin and within the native liver by reexamination 9 months 
later. 
qABil~ 21. INFLUENCE OF PREVIOUS MAJOR HEPATOBILIARY 
SURGERY" UPON RESULTS IN 40 CONSECUTIVE CASES 
(CYCLOSPORIN ERA) 
Previous major operation(s)" 
No major operation' 
No. 
14 
26 
Survival (months) 
>1 
10 
22 
>2 
10 
21 
>6 
10 
19 
" Six portal-systemic shunts (5 portacaval, 1 distal splenorenal), 5 
bile duct reconstructions, and 3 portoenterostomies (Kasai). 
h Previous exploration, open liver biopsy, cholecystectomy, T-tube 
insertion, and splenectomy were not counted as major prior procedures 
although the resulting vascular adhesions were usually troublesome. 
Twelve of the 26 patients had one or more of these "minor" previous 
operations including 4 cholecystectomies, 3 T-tube insertions, and 1 
splenectomy. 
take down a portacaval shunt. The portal vein after 
portacaval shunt (especially side to side) may have sub-
optimal length and can be so sclerotic that suturing is 
difficult or impossible. For patients who survive the first 
postoperative month, the background of previous major 
operations was no longer a factor (Table 21). These 
results suggest that a prudent decision may be against 
transplantation in patients with a complex surgical his-
tory, but that a "clean abdomen" is not a criterion of 
selection. 
THE OPTION OF AUXILIARY LIVER 
TRANSPLANTATION 
The alternative to orthotopic liver transplantation is 
transplantation of an extra liver (auxiliary transplanta-
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tion) without removal of the diseased native organ. Clin-
ical trials have been discouraging, as summarized by 
Fortner et al. (136) from the compiled world experience. 
Of nearly 50 well-documented auxiliary transplantations, 
only one was an unequivocal success. Subsequently a 
report from Paris described a second success (137). 
Our opinion has been that auxiliary liver transplanta-
tion should be restricted to patients with potentially 
reversible liver disease. In such a situation, the extra liver 
could be construed as a temporary support organ which 
can be removed later. However, we have encountered 
increasing numbers of patients whose portal vein has 
clotted in the hepatic hilum, making it technically im-
possible to consider liver replacement. Other candidates 
are those with extensive previous surgery in the right 
upper quadrant. Such patients can theoretically be 
helped by an auxiliary liver transplantation, particularly 
when the superior mesenteric vein or other distal tribu-
tories to the main portal circulation are still open. The 
optimal conditions for vascularization of an auxiliary 
liver graft require input from the portal circulation (2, 
32, 138, 139), largely because of its high concentrations of 
endogenous hormones. 
DETERMINANTS OF THE FUTURE 
THE QUESTION OF FINANCING 
Through 1980 in the United States, almost all liver 
transplantations were performed in the Clinical Research 
Centers (CRC) supported by the National Institutes of 
Health. The fraction of the per case cost born by this 
government agency shrank from year to year because of 
the increasing willingness of many third party insurance 
carriers to pay for part or all of the service. Third party 
payments were collected by the institution and remanded 
back to the National CRC headquarters which included 
such collections as part of the total grant funding. In the 
last years of the program at the University of Colorado, 
approximately 85% of CRC expenditures for liver trans-
plantation were paid for in this way. By having CRC 
support for the other 15%, it was not necessary to screen 
candidates for their ability to pay. This creative practice 
of federal and private cost sharing was conceived and 
made practical by Dr. William DeCaesare, Director of 
the Clinical Research Center Division, Bethesda, Md. 
Thanks to the administrative leadership that flowed from 
DeCaesare's office for more than 2 decades, almost all 
modern-day techniques of immunosuppression and 
transplantation of all organs, beginning with the kidney, 
were developed on CRC units. 
However, it is not reasonable to look indefinitely to the 
CRC for support. So far, none of the liver recipients at 
the University Health Center of Pittsburgh has been 
treated on the pediatric or adult CRC. The principal 
financing for their care has been from health insurance 
programs or, less commonly, from private sources includ-
ing community fund raising. The collection rate for bills 
has been greater than in the Colorado experience. With 
the exception of Blue Cross/Blue Shield and some health 
maintenance organization programs, the major health 
insurance companies have willingly accepted their re-
sponsibility for liver transplant candidates providing they 
were forewarned. The patterns of support from Blue 
Cross/Blue Shield have been irregular, probably because 
of their close association with MediCare. 
It is ironic that government decisions or opinions have 
impeded the movement of liver transplantation to the 
private sector of medicine. A pronouncement by a state 
or federal official of MediCare to the effect that liver 
transplantation is "experimental" and not fundable has 
often been the basis for a similar decision by regional 
officials of Blue Cross and/or Blue Shield or by a cost-
conscious health maintenance organization. Even so, a 
rapidly growing number of state (or Blue Cross) agencies 
(including those in Pennsylvania, New York, and New 
Jersey) have classified liver transplantation as a service. 
In spite of the advantage of a preexisting federally 
funded organ procurement network in the United States 
as part of the End Stage Renal Disease Program, the 
financing of liver procurement is not on a solid base. 
There are no formal guidelines about how to proportion 
the extra costs of removing extrarenal organs from a 
multiple organ donor, or how to ensure against the po-
tential malpractice and other liability that could be in-
curred. Etna Life Insurance Company, the carrier for the 
National Kidney Procurement Program, recently drew 
attention to these policy gaps in a document that had a 
chilling effect on some transplant coordinators. 
The approximate average cost of a liver transplanta-
tion in Pittsburgh has been $55,000 (range $23,000 to 
$150,000). The procedure offers hope of genuine rehabil-
itation. Dying of endstage liver disease with no hope of 
real recovery may be even more expensive. O'Donnell et 
al. (140) reported from Boston that the average cost of 
nonsurgical treatment of patient for variceal hemorrhage 
was $35,000. The use of any operative procedure in-
creased the total to $53,000. In many of our patients, the 
expenses incurred during repeated hospitalizations before 
transplantation dwarfed those incurred by transplanta-
tion itself. 
THE POTENTIAL INFLUENCE OF TRANSPLANTATION 
UPON THE PRACTICE OF HEPATOLOGY 
Five to 10 years from now, we believe that every major 
center for the treatment of liver disease will have either 
transplantation capabilities or direct access to this kind 
of service. The surgical techniques are within the grasp 
of many practicing surgeons. The frequency with which 
liver transplantation can be used will be great although 
this has not been properly assessed. Our estimate is that 
at least 20 centers will be required in the United States. 
Knowledge that the provision of new liver tissue is a 
realistic objective at the end of the line will influence 
decisions about treatment. It will be increasingly impor-
tant to avoid major and often futile surgical operations 
that jeopardize ultimate candidacy for transplantation. 
Fortunately, there are alternative approaches. Sclerosing 
therapy for the control of variceal hemorrhage instead of 
portal diversion has become increasingly accepted. 
"Interventional radiologists" often have been able to 
ameliorate duct strictures in sclerosing cholangitis and 
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other diseases as effectively as can surgeons at open 
operation. When procedures such as porticoenterostomy 
(Kasai) are performed in infants with biliary atresia, it 
will be worthwhile to avoid deviations from the standard 
Roux-Y technique and multiple reoperations which make 
transplantation difficult or impossible. 
The presence of regional units undoubtedly will move 
the timing of transplantation forward in the course of the 
disease. The fact that there has been a very high preop-
erative mortality of patients accepted as candidates for 
new livers is an indication of the lateness of referrals. 
Throughout the years, many others have reached the 
operating room in such appalling condition that there 
was little hope of survival. 
An avalanche of new scientific information should 
become available to hepatologists and surgeons as the 
result of progress in transplantation. Much has already 
been learned about the synthesis of proteins whose origin 
was not previously clear (2,9, 141-143). Further improve-
ments in surgical techniques and immunosuppression 
will increase the harvest. The history of medicine is that 
what was inconceivable yesterday and barely achievable 
today often becomes routine tomorrow. 
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